A vaccine administered during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and passing protection through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the timeframe when infants are particularly susceptible to the virus. RSV affects roughly 50 per cent of newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the immunisation protects vulnerable infants
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can range from causing mild, cold-like symptoms to causing severe chest infections that leave babies struggling to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with bad infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”
The pregnancy vaccine functions by stimulating the mother’s immune system to generate defence proteins, which are then transferred to the developing baby through the placenta. This mother-derived protection provides newborns with instant defence from the moment of birth, exactly when they are highly susceptible to RSV. The new study demonstrates that protection reaches approximately 85% when the vaccine is given at least four weeks before delivery. Even briefer gaps between vaccination and birth can still provide meaningful protection, with evidence suggesting that a fortnight’s interval is sufficient to shield babies born slightly early. Dr Watson advises pregnant women to have the vaccine at the recommended time, whilst noting that protection remains possible even if given later in the third trimester.
- Nearly 85 per cent coverage when immunised 4 weeks before birth
- Maternal antibodies transferred through placenta safeguard newborns from birth
- Coverage achievable with two-week gap before premature birth
- Vaccination during the third trimester still offers meaningful protection for infants
Compelling evidence from the latest research
The effectiveness of the RSV vaccine administered during pregnancy has been established through a extensive research programme undertaken in England, examining data from close to 300,000 babies born between September 2024 and March 2025. This represents approximately 90 per cent of all births during that half-year window, providing robust and representative data of the vaccine’s real-world impact. The study’s results have been validated by the UK Health Security Agency as showing robust protection for newborns during their most vulnerable early months. The scope of this study offers healthcare professionals and expectant parents with confidence in the vaccine’s demonstrated effectiveness across different groups and contexts.
The results present a compelling picture of the vaccine’s protective power. More than 4,500 babies were treated in hospital with RSV throughout the study period, with the overwhelming majority being infants whose mothers did not receive the vaccination. This stark contrast emphasises the vaccine’s essential role in protecting against serious illness in newborns. The drop in hospital admissions exceeding 80 per cent represents a major public health success, possibly preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms connected with severe RSV infection. These findings support the importance of the vaccination programme launched in the UK in 2024.
Study design and parameters
The research reviewed birth and hospitalisation records from England over a six-month timeframe, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to establish clear comparisons of RSV infection rates and hospitalisations. The large sample size and comprehensive nature of the data gathering ensured that findings were statistically significant and indicative of the general population, rather than individual cases or small subgroups.
The study specifically tracked hospital admissions for RSV among infants born to mothers who had been given the vaccine at different timepoints before delivery. This allowed researchers to establish the minimum time required between vaccination and birth for maximum protection, as well as to determine whether protection stayed significant with briefer timeframes. The methodology measured real-world outcomes rather than experimental conditions, providing tangible evidence of how the vaccine functions when given across diverse clinical settings and patient circumstances throughout pregnancy’s final trimester.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Comprehending RSV and its hazards
Respiratory syncytial virus, commonly referred to as RSV, is one of the leading causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity changing substantially from minor cold-type symptoms to serious, potentially fatal chest infections. Over 20,000 infants require intensive hospital care for RSV annually in the UK alone, placing enormous strain on children’s wards and newborn care units during busier periods.
The infection causes deep inflammation in the lungs and airways, making it perilously hard for vulnerable newborns to breathe and feed adequately. Parents often witness their babies visibly struggling, their chests heaving as they attempt to draw sufficient oxygen into their damaged lungs. Whilst the majority of babies recover with supportive care, a limited though important group succumb from RSV complications each year, making vaccination as prevention a critical public health imperative for defending the youngest and most at-risk members of society.
- RSV causes inflammation in lungs, leading to severe breathing difficulties in babies
- Approximately half of newborns catch the infection during their first few months alive
- Symptoms range from minor cold-like symptoms to life-threatening chest infections requiring hospitalisation
- Over 20,000 UK babies require serious hospital care for RSV each year
- Small numbers of infants die from RSV related complications each year in the UK
Take-up rates and professional guidance
Since the RSV vaccine programme began in 2024, health officials have stressed the importance of pregnant women getting their jab at the best time for greatest protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has underscored that timing is crucial for ensuring newborns benefit from the maximum immunity from birth. Whilst the evidence indicates that vaccination performed at least four weeks prior to delivery offers approximately 85% protection, experts recommend women to receive their vaccine as early as possible from 28 weeks of pregnancy onwards to increase the antibodies transferred to their babies through the placenta.
The communication from public health bodies stays clear: pregnant women ought to prioritise vaccination during their final three months, even if circumstances mean they cannot get vaccinated at the best timing. Dr Watson has reassured pregnant women that protection remains still achievable with reduced timeframes between vaccination and birth, including even a two-week gap for those giving birth ahead of schedule. This adaptable strategy recognises the realities of pregnancy and childbirth whilst maintaining strong protection for at-risk infants during their most critical early months when RSV represents the highest danger of severe infection.
Regional disparities in immunisation
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and deployment schedules have differed across different regions and NHS trusts. Some areas have achieved higher vaccination coverage among eligible pregnant women, whilst others remain focused to boost understanding and access to the jab. These regional differences demonstrate variations in healthcare infrastructure, engagement approaches, and local engagement efforts, though the overall statistics demonstrates consistently strong protection irrespective of geographical location.
- NHS trusts rolling out multiple messaging strategies to connect with pregnant women
- Regional disparities in vaccination coverage levels in different parts of England require targeted improvement
- Local healthcare systems tailoring initiatives to meet local requirements and situations
Practical implications and parent viewpoints
The vaccine’s remarkable effectiveness delivers real advantages for families throughout the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV prior to the introduction of this protective measure, the 80% decrease in admissions represents thousands of infants spared from serious illness. Parents no longer face the distressing scenario of watching their newborns gasping for air or labour to feed, symptoms that characterise critical RSV illness. The vaccine has fundamentally shifted the terrain of neonatal breathing health, offering expectant mothers a proactive tool to protect their most vulnerable children during those vital initial period.
For families like that of Malachi, whose serious RSV infection caused severe brain damage, the vaccine’s introduction carries significant emotional significance. His mother’s support of the jab emphasises the profound consequences that treatable infection can inflict on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates powerfully with parents now offered protection. The knowledge that such grave complications—hospital admission, oxygen dependency, neurological damage—are now mostly preventable has provided considerable reassurance to women in pregnancy navigating their final trimester, transforming what was once an predictable seasonal threat into a controllable health concern.